2014-05-14T14:30:45-05:00 2013-12-31 560574444 CHERRY BEKAERT LLP 1111 METROPOLITAN AVE STE 1000 CHARLOTTE NC 28204 990 2013-01-01 010648145 ORTHOCAROLINA RESEARCH INSTITUTE INC ORTH 7043232260 2001 VAIL AVENUE NO 300 CHARLOTTE NC 28207 CHRISTI CADD EXECUTIVE DIRECTOR 7043232260 2014-05-14 1 KELLIANNE F BENSON P01345659 7043771678 2013 2015-11-30 17:44:51Z CHRISTI CADD 2001 VAIL AVENUE NO 300 CHARLOTTE NC 28207 1685898 0 X WWW.ORTHOCAROLINARESEARCH.ORG X 2002 NC ORTHOCAROLINA RESEARCH INSTITUTE (THE "INSTITUTE" OR "OCRI") IS A NON-PROFIT ORGANIZATION DEDICATED TO PROMOTE, DEVELOP AND CONDUCT STATE OF THE ART SCIENTIFIC RESEARCH AND EDUCATIONAL PROGRAMS FOR THE ADVANCEMENT OF ORTHOPAEDIC CARE. OCRI WORKS BOTH INDEPENDENTLY AS WELL AS IN COLLABORATION WITH UNIVERSITIES, HOSPITALS, PHARMACEUTICAL COMPANIES, HEALTHCARE DEVICE MANUFACTURERS AND OTHER ACADEMIC AND RESEARCH ORGANIZATIONS TO FURTHER PROMOTE THE MISSION. 16 16 14 16 0 0 401738 570855 829927 1084526 29749 30517 0 0 1261414 1685898 0 0 0 0 703174 753137 0 0 90521 524242 710043 1227416 1463180 33998 222718 2273606 2667286 262539 208574 2011067 2458712 X THE INSTITUTE'S MISSION AND PRIORITIES ARE CENTRALLY FOCUSED ON: (1) IMPROVED PATIENT CARE, (2) HIGH QUALITY RESEARCH TO DEVELOP NEW AND INNOVATIVE ORTHOPAEDIC DEVICES AND TECHNOLOGIES, AND (3) COLLABORATIVE AND MULTIDISCIPLINE FORUMS TO FURTHER ENHANCE STATE-OF-THE-ART MEDICAL HEALTHCARE. THE INSTITUTE IS CURRENTLY PARTICIPATING IN 30 ON-GOING FDA REGULATED CLINICAL TRIALS AND APPROXIMATELY 80 SCIENTIFIC OUTCOMES STUDIES. 0 0 933140 1084526 CLINICAL TRIALS ARE DESIGNED TO DEVELOP NEW DEVICES, EVALUATE NEW MEDICATIONS, IMPROVE MATERIALS AND SYSTEMS, AND IMPROVE SURGICAL PROCEDURES. AT THE PRESENT TIME, THE ORTHOCAROLINA RESEARCH INSTITUTE IS FACILITATING THIRTY FDA-CONTROLLED CLINICAL TRIALS THAT SERVE AND SUPPORT THE PUBLIC IN PROVIDING STATE-OF-THE-ART SURGICAL AND NON-SURGICAL TREATMENT OPTIONS. SCIENTIFIC OUTCOMES STUDIES ARE DESIGNED TO PROVIDE DATA AND INFORMATION SUPPORTS, AND/OR OPPOSES, NEW METHODS OF TREATMENT, AND DETERMINES NEW TECHNOLOGY IN ORDER TO PROVIDE THE BEST TREATMENT OPTIONS FOR PATIENTS. CLINICAL RESEARCH STUDIES ALLOW PHYSICIANS TO PROVIDE IMPROVED PATIENT CARE, EVALUATE THE RESULTS OF NEW PROCEDURES, INSURE THAT THE TREATMENTS PROVIDED ARE THE BEST AVAILABLE, PROMOTE COST EFFECTIVE TREATMENT PROGRAMS, AND DOCUMENT PATIENT SATISFACTION AND QUALITY OF LIFE.ALL CLINICAL TRIALS AND SCIENTIFIC OUTCOMES STUDIES ARE REVIEWED AND APPROVED BY THE INSTITUTE'S RESEARCH ADVISORY COMMITTEE (RAC), THE INSTITUTIONAL REVIEW BOARD (IRB) AT CAROLINAS HEALTHCARE SYSTEM (CHS) OR CHARLOTTE ORTHOPEDIC HOSPITAL (COH) PRIOR TO IMPLEMENTATION. STRINGENT PROTOCOLS ARE REQUIRED TO ENSURE THE SAFETY OF ALL PARTICIPATING INDIVIDUALS AND TO MAKE CERTAIN THAT PARTICIPATING SURGEONS FOLLOW THE SAME STUDY PROCEDURES AND GUIDELINES. 112465 THE ORTHOCAROLINA RESEARCH INSTITUTE HAS HOSTED THE OSCAR MILLER DAY SYMPOSIUM FOR OVER 30 YEARS. THIS CONTINUING MEDICAL EDUCATION EVENT HOSTS 300 TO 450 ORTHOPEDIC PROVIDERS AND ALLIED HEALTH PROFESSIONALS ANNUALLY. THE ACCREDITED ONE DAY SYMPOSIUM IS PRICED ONLY TO COVER COSTS AND ROTATES ORTHOPEDIC SUB-SPECIALTIES EACH YEAR. THE PROGRAM INVITES GUEST SPEAKERS FROM ACROSS THE COUNTRY WHO ARE KNOWN LEADERS IN THE FIELD OF ORTHOPEDICS TO HIGHLIGHT NEW TRENDS, TECHNIQUES AND RESEARCH. THE EVENT IS MARKETED TO THE SOUTHEASTERN UNITED STATES. 83671 THE IPASS (INJURY PREVENTION ACROSS SPORTS WITH SCIENCE) CHARITY EVENT ORIGINATED IN 2013. THIS EVENT IS MEANT TO BE A FUNDRAISER BUT MORE IMPORTANTLY AN AVENUE TO EDUCATE THE LAY COMMUNITY ABOUT THE IMPORTANCE OF INJURY PREVENTION AND ORTHOPEDIC RESEARCH. THE EVENT INCLUDES A SILENT AUCTION, SEATED DINNER, GUEST CELEBRITY TABLE HOSTS, AND A PROGRAM FULL OF EDUCATIONAL PRESENTATIONS HIGHLIGHTING THE IMPORTANCE OF ORTHOPEDIC RESEARCH AND ADVANCEMENT. 1129276 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 27 0 14 1 0 0 0 0 0 1 1 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NC X CHRISTI CADD 7043232260 2001 VAIL AVENUE STE 300 CHARLOTTE NC 28207 PATRICK M CONNOR MD DIRECTOR 1.00 X 0 0 0 WALTER B BEAVER MD DIRECTOR 1.00 X 0 0 0 ROBERT A HEYER MD DIRECTOR 1.00 X 0 0 0 MR RICHARD E THIGPEN DIRECTOR 1.00 X 0 0 0 J MICHAEL WATTENBARGER MD DIRECTOR 1.00 X 0 0 0 MR JOHN L FRALEY JR DIRECTOR 1.00 X 0 0 0 MR FRED R JONES DIRECTOR 1.00 X 0 0 0 MORRY JOHNSTON DIRECTOR 1.00 X 0 0 0 MR WESLEY WALLS DIRECTOR 1.00 X 0 0 0 GLENN GASTON MD DIRECTOR 1.00 X 0 0 0 HARVEY GANTT DIRECTOR 1.00 X 0 0 0 CHARLES M EAST III DIRECTOR 1.00 X 0 0 0 ROBERT ANDERSON DIRECTOR 1.00 X 0 0 0 BRANDON BOYD DIRECTOR 1.00 X 0 0 0 VELVA WOOLLEN DIRECTOR 1.00 X 0 0 0 WILLIAM L GRIFFIN MD CHAIRMAN 3.00 X X 0 0 0 CHRISTI CADD EXECUTIVE DIRECTOR 40.00 X 103862 0 3116 103862 0 3116 1 0 0 0 0 570855 570855 RESEARCH FOR PUBLIC BE 900099 1084526 1084526 1084526 20742 20742 9775 0 9775 9775 9775 1685898 1084526 0 30517 106978 55847 51131 501290 501290 15960 14618 1342 80360 73605 6755 48549 44468 4081 9881 9881 17044 17044 12450 12450 17345 17345 41406 41406 8791 8791 16357 16357 STUDY EXPENSES 337904 337904 MISCELLANEOUS 136081 45560 90521 OSCAR MILLER DAY EXPENS 96310 96310 EQUIPMENT 11240 11240 5234 5234 1463180 1129276 243383 90521 528523 371331 251469 363941 13878 13878 0 0 1493614 1932014 2273606 2667286 262539 208574 262539 208574 X 2011067 2458712 2011067 2458712 2273606 2667286 222718 224927 0 X X 0 1 X 1 0 X 219517 372602 577797 401738 570855 2142509 490421 575108 709928 829927 1084526 3689910 709938 947710 1287725 1231665 1655381 5832419 194517 303121 387926 238758 154230 1278552 0 194517 303121 387926 238758 154230 1278552 4553867 26282 35601 24848 25755 20742 133228 26282 35601 24848 25755 20742 133228 736220 983311 1312573 1257420 1676123 5965647 0.76330 0.73580 0.02230 0.02650 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 13878 13878 0 0 FIXED INCOME POOL 332306 F EQUITY POOL 1134093 F PRIVATE INVESTMENT FUNDS 465615 F 1932014 X 1655381 0 1655381 30517 30517 1685898 1446136 0 1446136 17044 17044 1463180 PART X, LINE 2: THE INSTITUTE IS LIABLE FOR FEDERAL AND STATE TAXES ON ANY UNRELATED BUSINESS INCOME, AS DEFINED IN THE INTERNAL REVENUE CODE. THE INSTITUTE'S POLICY IS TO RECORD A LIABILITY FOR ANY TAX POSITION TAKEN THAT IS BENEFICIAL TO THE INSTITUTE, INCLUDING ANY RELATED INTEREST AND PENALTIES, WHEN IT IS MORE LIKELY THAN NOT THE POSITION TAKEN BY MANAGEMENT WITH RESPECT TO A TRANSACTION OR CLASS OF TRANSACTIONS WILL BE OVERTURNED BY A TAXING AUTHORITY UPON EXAMINATION. MANAGEMENT BELIEVES THERE ARE NO SUCH POSITIONS AS OF DECEMBER 31, 2013 AND 2012 AND, ACCORDINGLY, NO LIABILITY HAS BEEN ACCRUED. THE INSTITUTE IS NO LONGER SUBJECT TO TAX EXAMINATIONS FOR YEARS PRIOR TO 2010. PART XI, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT INCOME SHOWN AS CHANGE IN BENEFICIAL INTEREST TRUST ON FINANCIALS 20,742. REALIZED GAIN SHOWN AS CHANGE IN BENEFICIAL INTEREST IN TRUST ON FINANCIALS 9,775. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 IS EMAILED TO ALL BOARD MEMBERS FOR THEIR REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C DIRECTORS, OFFICERS AND KEY EMPLOYEES CERTIFY THAT THEY READ THE ORGANIZATION'S CONFLICT OF INTEREST POLICY AND HAVE DISCLOSED ANY RELATIONSHIPS WITH ANY OF THE ORGANIZATION'S CONTRACTING PARTIES ON THE ORGANIZATION'S CONFLICT OF INTEREST FORM. THE EXECUTIVE DIRECTOR REVIEWS THESE CERTIFIED FORMS, INCLUDING COMPARISONS TO THE PRIOR YEAR'S DISCLOSURES, AND CONFIRMS ANY CHANGES WITH THE SIGNERS. NO QUESTIONABLE RELATIONSHIP HAS BEEN NOTED OR BROUGHT TO THE ATTENTION OF THE APPROPRIATE GOVERNANCE GROUP. AT THE FEBRUARY MEETING OF THE FINANCE/AUDIT COMMITTEE, THE EXECUTIVE DIRECTOR REVIEWS WITH THE COMMITTEE THE COMPLIANCE STEPS TAKEN AND THE RESULTS FOR THE YEAR, AND CONFIRMS THAT NOTHING HAS BEEN BROUGHT TO HER ATTENTION DURING THE YEAR WHICH WOULD REQUIRE FURTHER EXAMINATION OF THE CURRENT CONFLICT OF INTEREST CERTIFICATIONS. THIS REVIEW IS INCLUDED AS PART OF THE COMMITTEE'S NORMAL REPORT TO THE BOARD REGARDING THE COMMITTEE'S ACTIVITIES. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE COMMITTEE COMPLETES A PERFORMANCE EVALUATION AND ASSESSMENT OF SALARY FOR THE EXECUTIVE DIRECTOR ANNUALLY. THE EXECUTIVE COMMITTEE CONSISTS OF THE CHAIRMAN OF THE BOARD, CHAIRMAN OF THE RESEARCH ADVISORY COMMITTEE AND THE EXECUTIVE DIRECTOR. THE EXECUTIVE DIRECTOR IS A MEMBER OF THE EXECUTIVE COMMITTEE; HOWEVER, HAS NO VOTE WHEN IT COMES TO PERSONAL PERFORMANCE AND SALARY. THE ORTHOCAROLINA RESEARCH INSTITUTE SHARES HUMAN RESOURCE SERVICES WITH ORTHOCAROLINA, PA. THE ORTHOCAROLINA, PA HUMAN RESOURCE DEPARTMENT PERFORMS PERIODIC REVIEWS OF ALL POSITIONS TO ENSURE SALARIES ARE COMPETITIVE AND FAIR WITHIN THE MARKET. IT IS COMMON PRACTICE FOR SALARIES TO INCREASE 3-5% DEPENDING ON INDIVIDUAL PERFORMANCE ANNUALLY. THE EXECUTIVE DIRECTOR BUDGETS SALARY INCREASES ANNUALLY AND SHOULD A STAFF SALARY INCREASE GREATER THAN THE 3-5% EXPECTED RANGE, IT IS PRESENTED BEFORE THE EXECUTIVE COMMITTEE FOR APPROVAL. ALL SALARY ADJUSTMENTS MADE BY THE ORTHOCAROLINA RESEARCH INSTITUTE ARE DOCUMENTED AND SUBMITTED TO THE ORTHOCAROLINA PA, HUMAN RESOURCE DEPARTMENT FOR FINAL APPROVAL BEFORE SUBMITTING TO PAYROLL. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, POLICIES AND PROCEDURES AND FINANCIAL STATEMENTS ARE HELD IN THE OFFICE OF THE EXECUTIVE DIRECTOR. SUCH DOCUMENTS ARE AVAILABLE FOR REVIEW UPON REQUEST.